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Abstract
Identification of susceptibility genes for essential hypertension in humans has been a
challenge due to its multifactorial pathogenesis complicated by gene-gene and gene-
environment interactions, developmental programing and sex specific differences. These
concurrent features make identification of causal hypertension susceptibility genes with a
single approach difficult, thus requiring multiple lines of evidence involving genetic, bio-
chemical and biological experimentation to establish causal functional mutations. Here we
report experimental evidence encompassing genetic, biochemical and in vivomodeling that
altogether support ATP1A1 as a hypertension susceptibility gene in males in Sardinia, Italy.
ATP1A1 encodes the α1Na,K-ATPase isoform, the sole sodium pump in vascular endotheli-
al and renal tubular epithelial cells. DNA-sequencing detected a 12-nucleotide long thymi-
dine (12T) insertion(ins)/deletion(del) polymorphism within a poly-T sequence (38T vs 26T)
in the ATP1A1 5’-regulatory region associated with hypertension in a male Sardinian popu-
lation. The 12T-insertion allele confers decreased susceptibility to hypertension (P = 0.035;
OR = 0.50 [0.28–0.93]) accounting for 12.1 mmHg decrease in systolic BP (P = 0.02) and
6.6 mmHg in diastolic BP (P = 0.046). The ATP1A1 promoter containing the 12T-insertion
exhibited decreased transcriptional activity in in vitro reporter-assay systems, indicating
decreased α1Na,K-ATPase expression with the 12T-insertion, compared with the 12T-
deletion ATP1A1 promoter. To test the effects of decreased α1Na,K-ATPase expression on
blood pressure, we measured blood pressure by radiotelemetry in three month-old, highly
inbred heterozygous knockout ATP1A1+/−male mice with resultant 58% reduction in
ATP1A1 protein levels. Male ATP1A1+/−mice showed significantly lower blood pressure
(P< 0.03) than age-matched male wild-type littermate controls. Concordantly, lower
ATP1A1 expression is expected to lower Na-reabsorption in the kidney thereby decreasing
sodium-associated risk for hypertension and sodium-induced endothelial stiffness and dys-
function. Altogether, data support ATP1A1 as a hypertension susceptibility gene in a male
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Sardinian population, and mandate further investigation of its involvement in hypertension
in the general population.
Introduction
Essential hypertension is a complex multifactorial condition influenced by both genetic and en-
vironmental factors [1]. As a complex polygenic disorder, identification of hypertension sus-
ceptibility genes has been difficult requiring multiple lines of evidence to prove their causal
roles in essential hypertension pathogenesis [2,3]. The a1 Na,K-ATPase (ATP1A1) is the sole
active Na+ transporter in the renal basolateral epithelia throughout the nephron [4–6] and in
vascular endothelium [7], and given the role of sodium as a major risk factor for hypertension,
the ATPA1 gene is a logical candidate gene for susceptibility to salt-sensitive ‘essential’ or poly-
genic hypertension [4–6]. The investigation of ATP1A1 in human essential hypertension is
supported by cumulative evidence obtained in the Dahl salt-sensitive hypertensive rat model,
linking ATP1A1 to salt-sensitive hypertension [8–12], documenting a functionally significant
variant [8] confirmed by ligase chain reaction-assays [13], protein Edman degradation se-
quencing and amplification-independent allele-specific PCR-assays [11,13]. Furthermore, res-
cue of the salt-sensitive hypertensive phenotype was attained through transgenic expression of
the ‘wild-type’ Dahl salt-resistant ATP1A1 variant in Dahl S rats [10].
In humans, ATP1A1 single-point and haplotype association analyses of a Sardinian hyper-
tensive/normotensive> 60 yrs cohort demonstrated gender-specific association of the
ATP1A1 locus with hypertension in males [14]. These results corroborated earlier reports link-
ing the ATP1A1 locus with hypertension susceptibility in a Quebec family study [15] and our
earlier observations in the same Sardinian cohort using microsatellite markers in close proxim-
ity to the ATP1A1 locus [16]. The association of the haplotype defined by single nucleotide
polymorphisms (SNPs) located in the ATP1A1 5’ flanking regulatory region suggested that the
ATP1A1 promoter region is a likely location of putative molecular variants contributing to
modulation of hypertension susceptibility in this population [14]. Given the association of
ATP1A1 with hypertension in a rat model and in a Sardinian cohort, and the following facts:
that ATP1A1 is the sole Na,K-ATPase a-subunit isoform in vascular endothelial cells [7] and
renal tubular epithelial cells involved in Na-reabsorption [5,6], that increased sodium levels is
implicated in endothelial stiffness [17,18], and that sodium is a known risk factor for arterial
stiffness [19] and hypertension [5], it becomes apparent that the ATP1A1 gene is a logical can-
didate hypertension gene. We therefore, investigated putative functionally-significant DNA se-
quence-variants within the ATP1A1 5’ regulatory region that might contribute to susceptibility
or resistance to essential hypertension in the Sardinian cohort of hypertensive and normoten-
sive people> 60 years of age queried in the association study [14].
Results
Scanning of ATP1A1 5’-regulatory region for candidate variants
To elucidate potential variants within the ATP1A1 promoter region we cloned and sequenced a
4551 bp DNA fragment from three patients carrying haplotypes associated with hypertension
and from three subjects carrying haplotypes associated with normotension respectively that
were previously identified in the Sardinian cohort in prior association studies [14]. We note
that normotensive individuals were limited to 60 years and older to ascertain normotension
 60 years, and since hypertensive-normotensive patient age-matching is not important given
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that age differences do not affect DNA-sequence variants, unlike physiological or biochemical
assays.
We used as forward primer: 50-AGA-TCA-TGA-GGC-TGA-GTG-AG-30 and as reverse
primer: 50-TTC-CAT-TTT-GGC-GAT-GGT-G-30 which span chromosome (Chr)-1 coordi-
nates 116363538–116368089 of the 5’-regulatory region of ATP1A1 (Fig. 1). DNA sequence
analysis detected a 12T-insertion/deletion (12T-ins/del) polymorphism involving a poly-T
sequence (38T/26T) in close proximity to a putative TATAAA-box in the promoter region of
the ATP1A1 gene (Fig. 1A–1B) that could potentially modulate ATP1A1 transcription. Con-
cordantly, a potential RNA initiation site is identified by consensus sequence in close proximity
to nucleotide 116,366,000 within the predicted exon 1 (5’-Untranslated region) and supported
by RNAseq data (S1 Fig.).
Association results of 12T ins/del (ATP1A1) polymorphism with essential
hypertension
For our genetic analysis we utilize a case control paradigm focusing on the extreme of the
population as contrasting samples, i.e.: hypertensives with BP> 160/95 mmHg and normoten-
sives subjects with BP< 138/85 mmHg. Since essential hypertension is a late-onset disease, to
exclude erroneous control subjects with late-onset hypertension, normotensive controls were
limited to those older than 60 years of age. To ascertain phenotype accuracy, we used stringent,
clinically pertinent criteria to distinguish hypertensive cases and normotensive controls, thus
ascertaining a robust case-control cohort. Phenotypic characteristics of the Sardinian sample
are shown in Table 1. Stratification by gender did not significantly change the mean BP values
when comparing hypertensives versus normotensives (Table 1).
After identification, we next tested whether the 12T ins/del polymorphism per se is associated
with susceptibility to hypertension in our case-control cohort. As shown in Table 2, the 12T-ins
(minor) allele is protective for hypertension susceptibility in our Sardinian cohort and exhibits
sex-specificity with significantly increased frequencies of ATP1A1 12T-ins alleles only in males
(P = 0.035, OR = 0.50, Table 2). To further corroborate these association results we analyzed the
ATP1A1 12T-ins/del polymorphism based on blood pressure as a quantitative trait. Consistent
with the results obtained in the case-control analysis, male subjects homozygous and heterozy-
gous for the ATP1A1 12T-ins allele had lower blood pressure (−12.1 mmHg for SBP, P = 0.02;
−6.6 mmHg for DBP, P = 0.046, Table 3) than homozygous carriers for the ATP1A1 12T-del
allele. Allele-specific differential BP levels suggest that the 12T-ins/del polymorphism is most
likely a functional variant which contribute to differential susceptibility to essential hypertension
in males in the Sardinian cohort studied.
Transcriptional activity of ATP1A1 promoter regions containing the
12T-ins/del alleles
Since the polymorphism is located close to a TATAAA-box in the promoter region, we next
tested the differential effects of 12T-insertion versus 12T-deletion on transcriptional activity of
the ATP1A1 promoter using promoter-reporter minigene constructs (Fig. 1C). We used three
cell lines: two of renal origin (HEK293, human embryonic kidney cell line; Cos1, monkey kid-
ney cell line) and a human mammary tumor cell line (MDA-MB-468). As shown in Fig. 1D,
the ATP1A1 p12T-ins minigene construct (testing the 12T-insertion allele conferring protec-
tion to high blood pressure) exhibited significantly lower transcriptional activity than the
p12T-del minigene construct (12T-deletion allele associated with high blood pressure) in the
three cell lines tested (in Cos1, P< 0.05; in HEK293 and MDA-MB-468, P< 0.01). These ob-
servations show that the 12T-ins/del is a functional variant that modulates ATP1A1
12T-Insertion in ATP1A1 Promoter and Hypertension Susceptibility
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Figure 1. Identification of the 12T-ins/del polymorphism in the ATP1A1 promoter region and transcriptional activity of ATP1A1 promoter variants.
(A) Nucleotide sequence spanning the poly-T sequence involved in the 12T-ins/del polymorphism from the two ATP1A1 (p12T ins, p12T del) reporter gene
constructs utilized in the transcriptional assays. On right detection of 12T-insertion and 12T-deletion alleles by PCR-amplification followed by denaturing
polyacrylamide gel (6%) electrophoresis used for genotyping of the Sardinian cohort. (B) Illustration of the ATP1A1 promoter region. Non-coding exon is
presented as open box and exon encoding the NH2-terminal region is presented as black box. Sequence and location of the ATP1A1 12T-ins/del
polymorphism is shown. The positions of TATAAA box, INR (initiator) and DPE (downstream promoter element) core promoter elements within ATP1A1
promoter are shown. Core promoter elements were identified based on 100% homology with corresponding consensus sequences [39,40]. (C) Schematic of
two ATP1A1 (p12T ins, p12T del) reporter gene constructs. (D) Relative transcriptional activity of 12T-insertion (p12T ins) and 12T-deletion (p12T del) gene
constructs in Cos1, HEK293 and MDA-MB-468 cells. *, P< 0.05; **, P< 0.01 (two-tailed student t-test).
doi:10.1371/journal.pone.0116724.g001
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transcription, hence impacting levels of ATP1A1 expression with the 12T-insertion expected
to decrease a1Na,K-ATPase levels, and the 12T-deletion expected to increase it. One would
therefore predict that in vivo, a decrease in ATP1A1 expression would lead to a decrease in
blood pressure in male subjects and vice versa, an increase in ATP1A1 levels would result in
an increment in blood pressure, given that the a1Na,K-ATPase is involved in renal Na-
reabsorption, and hence sodium levels.
Effect of ATP1A1 haploinsufficiency on blood pressure
To assess if changes in ATP1A1 levels could modulate blood pressure in vivo, in a manner that
is consistent with the 12T-ins/del functional variants characterized in in vitro transcriptional
assays we measured blood pressure by radiotelemetry in four heterozygous ATP1A1 knockout
mice (ATP1A1+/−) and five wild type male mice expressing differential ATP1A1 protein levels.
Because of differential blood pressure levels in non-inbred mice, we first inbred the ATP1A1
knockout mouse line to greater than 99.5% C57BL/6 background. Since the association is
Table 1. Characteristics of the study population.
Variable NTa (total) HTb (total) Male NT Female NT Male HT Female HT
n 279 433 131 148 237 196
Age, yc 65.4  10.6 51.0  10.2 66.1  8.9 64.8  11.9 51.8  10.6 50.0  9.6
BMId, Kge/m2 26.2  3.9 27.7  4.0 26.3  3.0 26.2  4.6 28.0  3.8 27.4  4.3
SBPf, mmHgg 127.6  11.3 174.4  14.7 127.9  10.7 127.4  11.9 173.2  14.6 175.9  14.8
DBPh, mmHg 77.6  7.2 110.5  9.9 77.2  6.8 78.0  7.4 111.9  10.4 108.8  9.0
a, Normotensives
b, hypertensives; total, male + female subjects
c, years
d, body mass index
e, kilogram per meter squared
f, systolic blood pressure
g, millimeters mercury
h, diastolic blood pressure.
doi:10.1371/journal.pone.0116724.t001
Table 2. ATP1A1 single variant association results.
Polymorphism Alleles Protective allele Controls Cases OR (95% c.i.) A/A vs. Aa + aa P value
Freqa AA/Aa/aab Freqa AA/Aa/aab
Male + Female cohort
12T-ins/del 38T/26T 38T 0.109 209/40/8 0.071 369/46/7 0.63 (0.41–0.96) 0.035
Female cohort
12T-ins/del 38T/26T 38T 0.109 114/18/6 0.078 165/24/3 0.78 (0.43–1.42) 0.442
Male cohort
12T-ins/del 38T/26T 38T 0.109 95/22/2 0.065 204/22/4 0.50 (0.28–0.93) 0.035
Genotype counts for cases and controls are shown.
a, Minor allele frequency (38T)
b, For 12T-ins/del, the genotype counts are for 12T-del12T-del/12T-del12T-ins/12T-ins12T-ins
OR, odds ratio
c.i., conﬁdence interval
P, Two sided Fisher’s exact P. ATP1A1, α1 Na,K-ATPase.
doi:10.1371/journal.pone.0116724.t002
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male-specific, we then studied 3-month old male heterozygous ATP1A1+/− knockout mice
compared to age-matched littermate wild-type ATP1A1+/+ male mice on regular mouse
chow. Analysis of ATP1A1 protein levels by western blot analysis revealed that heterozygous
ATP1A1+/− knockout male mice expressed 58% less ATP1A1 protein levels in kidney
(Fig. 2A-2B) compared to wild type mice, as expected from haploinsufficiency. These data are
concordant with decreased ATP1A1 levels in the heart of non-inbred ATP1A1+/− heterozygous
knockout mice [20].
To study the effects on blood pressure, we obtained radiotelemetric blood pressures in
3-month old, inbred male heterozygous ATP1A1+/− knockout and wild-type littermate mice
during a 24-hour no-disturbance period. As predicted, the heterozygous ATP1A1+/−mice ex-
hibited lower systolic blood pressures (mean sem 107.63 4.8 mmHg) compared to male
wild-type controls (124.42 3.8 mmHg; P< 0.03) (Fig. 2C). Notably, we detected equivalent
measures of heart rate (Fig. 2D) and activity (Fig. 2E). These in vivomouse model studies show
that the genetic decrease in ATP1A1 expression resulted in lower blood pressure set-points,
consistent with predictions from ATP1A1’s known role in Na-reabsorption in the kidney [5,6],
and the causal role of increased sodium levels on endothelial stiffness [17,18].
Discussion
Identification of genes underlying susceptibility to essential hypertension in humans has been
a challenge due to its complex multifactorial etiology involving multiple genetic and environ-
mental factors, and compounded by gene-gene and gene-environment interactions, develop-
mental programing and gender-specific modulation. These characteristics make it difficult to
elucidate causative genes with a single approach, thus requiring multiple lines of evidence in-
volving genetic, biochemical and biological experimentation to establish causation. A priori, in
order to demonstrate a hypertension susceptibility gene one should provide at the minimum
evidence for: 1) genetic association of the gene in question with essential hypertension in a
human population, 2) elucidation and genetic association of specific functional variants that
might contribute to susceptibility or resistance to high blood pressure and 3) demonstration in
Table 3. Analysis of ATP1A1 (12T-ins/del) variants based on blood pressure as a quantitative trait.
Genotypes na Mean SBPb  s.e.m. Δ SBP P Mean DBPc  s.e.m. Δ DBP P
Male  Female cohort
12T-del/del 577 158.8  1.5 99.9  1.0
[12T-ins/del  12T-ins/ins] 101 151.2  3.2 7.3 0.056 95.6  2.3 4.3 0.078
Female cohort
12T-del/del 279 156.7  2.2 95.9  1.4
[12T-ins/del  12T-ins/ins] 51 154.2  4.6 2.5 0.707 94.3  2.6 1.6 0.798
Male cohort
12T-del/del 298 160.2  2.0 103.5  1.4
[12T-ins/del  12T-ins/ins] 50 148.1  4.5 12.1 0.020 96.9  3.7 6.6 0.046
Blood pressures were adjusted for age, body mass index and case/control status.
a Number of individuals
b Systolic blood pressure in mmHg
c Diastolic blood pressure in mmHg
s.e.m., standard error of the mean
Δ SBP, difference in systolic blood pressure
Δ DBP, difference in diastolic blood pressure
P, Mann-Whitney Rank Sum Test P values.
doi:10.1371/journal.pone.0116724.t003
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different biological experimental systems that the effect of specific functional variants on blood
pressure are consistent with the genetic association results, and concordant with known physi-
ological functions [2,3]. In compliance with all three a priori requirements for the definition of
a susceptibility gene in a complex trait, here we present experimental data encompassing genet-
ic, biochemical and an in vivo biological system that collectively support the hypothesis that
the ATP1A1 gene is a hypertension susceptibility gene in males in a Sardinian cohort. We
found a 12T-insertion (ins) polymorphism involving a poly-T sequence (38T vs 26T) within
the ATP1A1 5’-regulatory region that is associated with decreased susceptibility to essential hy-
pertension in a male Sardinian cohort, and causes decreased ATP1A1 transcriptional activity,
hence decreased ATP1A1 expression, in in vitro reporter-assays compared with the ATP1A1
promoter containing the 12T-deletion. Based on a1Na,K-ATPase key role in renal Na-reab-
sorption [5,6] and the role of sodium in hypertension [5] and endothelial stiffness [17,18], the
expected functional consequences of lower blood pressure due to lower ATP1A1 expression
was demonstrated by lower blood pressure in ATP1A1+/−male mice haploinsufficient for
ATP1A1 with 58% reduction in ATP1A1 protein in kidneys.
Importantly, these findings are concordant with cumulative evidence obtained in animal
models of polygenic hypertension linking ATP1A1 to salt-sensitive hypertension [8–12] albeit
with different molecular basis, and human studies showing association of the ATP1A1 locus
with hypertension [14–16]. Additionally, the sex-specific effects of the ATP1A1 promoter vari-
ants on hypertension susceptibility are also consistent with our studies in the Dahl rat model of
salt-sensitive hypertension showing stronger linkage of the ATP1A1 locus with salt-sensitive
hypertension in the F2 male population [12].
Moreover, since the a1Na,K-ATPase isoform, encoded by the ATP1A1 gene, is the sole ac-
tive sodium (Na) transporter in the renal basolateral epithelia throughout the nephron [4–6],
Figure 2. Analysis of ATP1A1 protein expression, blood pressure, heart rate and activity in
heterozygous ATP1A1+/− and wild-typemale mice. (A) Western blot analysis of ATP1A1+/− and wild type
mouse whole kidney extracts (30 μg) reacted with anti-mouse ATP1A1 and anti-mouse βActin polypeptides.
(B) Densitometry analysis of samples shown in (A) detecting 58% decrease ATP1A1 levels in ATP1A1+/−
kidneys. (C) Mean systolic blood pressure sem (SBP; mmHg). (D) Mean heart rate sem (beats/min;
BPM). (E) Mean activity sem (Counts/min) in ATP1A1+/− (solid bars, n = 4) and wild-type (open bars, n = 5)
male mice. * P< 0.03, ** P = 0.015 (two-tailed student t-test).
doi:10.1371/journal.pone.0116724.g002
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any changes in ATP1A1 levels and/or activity will impact renal Na reabsorption, hence Na ho-
meostasis and blood pressure [4–6]. The molecular phenotype of the ATP1A1 12T-insertion
variant (protective allele) is consistent with its association with normotension (lower blood
pressure) since the ATP1A1 promoter harboring the 12T-insertion polymorphism exhibited
lower transcriptional activity which a priori results in lower renal ATP1A1 RNA and hence,
lower ATP1A1 protein levels which predicts lower blood pressure. Importantly, this a priori
expectation was confirmed in in vivo model studies of highly inbred heterozygous ATP1A1+/−
male mice with 58% reduced levels of renal a1 Na,K-ATPase and significantly lower blood
pressure compared to age-matched male wild type control mice. Additionally, since increasing
sodium levels within known ‘normal range from 139 mM to 145 mM sodium is associated with
increasing endothelial stiffness in vitro (3–25% increase [17,18,21], collective observations
raise the hypothesis lower ATP1A1 transcription and expression could also decrease endotheli-
al stiffness via maintaining lower sodium levels given the same sodium-intake and/or via
dampening the crosstalk between endothelial ENac (epithelial Na-channels) and a1Na,K-
ATPase [22].
From a molecular genetic perspective, increasing evidence of insertion-deletion polymor-
phisms in gene promoter regions affecting susceptibility to complex disorders suggest that this
type of variants are more common than originally considered. A six-nucleotide insertion-
deletion polymorphism in the CASP8 promoter has been associated with susceptibility to mul-
tiple cancers with the deletion variant having reduced caspase-8 activity and conferring de-
creased risk of cancer [23]. Similarly, a five-nucleotide insertion-deletion polymorphism in the
IRF5 promoter was found to be associated with inflammatory bowel disease with the insertion
allele enhancing the risk of inflammatory bowel disease [24]. A functional 44 bp ins/del poly-
morphism in the promoter region of 5-HTTLPR (serotonin transporter) affecting 5-HTTLPR
expression has been associated with major depressive disorder [25]. More recently, a functional
ATTG ins/del polymorphism in the NFKB1 5’-regulatory region modulating NFKB1 protein
levels has been related to the risk of coronary heart disease [26] and risk of multiple cancers
[27–29]. Interestingly, an ins/del polymorphism within the p21 (Waf1/Cip1) promoter region
involving a poly-T sequence (11T/9T) has been associated with gastric cancer [30], however
the functionality of this polymorphism has not been determined. Thus, our finding of an asso-
ciation of a 12T-ins/del polymorphism involving a poly-T sequence (38T/26T) with essential
hypertension is not unprecedented, and is concordant with the inherent potential of a func-
tional variant in a gene’s regulatory promoter region to provide a molecular mechanism for
gene-environment interactions that result in a disease-phenotype only when both variant and
environmental factor are present.
Although, the precise molecular mechanism as to how the 12T-ins/del polymorphism af-
fects the transcription initiation complex remains to be elucidated, susceptibility-polymor-
phisms in gene regulatory promoter regions provide a putative mechanism for gene-
environmental factor interactions through the differential modulation of transcription specific
to the susceptibility-variant and environmental factor interaction. This notion would imply
that replication in other cohorts could be dependent on similar gene-environment interactions
including developmental programming, and that phenotyping of hypertension cohorts need to
incorporate environmental factor exposure and developmental programming. In retrospect,
the Sardinian island cohort provides relative homogeneity in terms of genetic background and
environmental factors.
Genome-wide association studies involving large populations have failed to detect signifi-
cant association between ATP1A1 and high blood pressure [31]. A number of reasons may ac-
count for this negative finding, including intrinsic genetic heterogeneity of human populations,
differential accuracy and/or modality in trait measurements (blood pressure), differential
12T-Insertion in ATP1A1 Promoter and Hypertension Susceptibility
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exclusion criteria for affected individuals, exclusion of putative sex-specific effects on the phe-
notype in the analytical paradigm, and gestational risk factors. For our genetic analysis we uti-
lized a case control paradigm focusing on the extreme of the population as contrasting samples
(hypertensives with BP> 160/95 mmHg versus normotensives subjects with BP< 138/85
mmHg). Moreover, since essential hypertension is a late-onset disease, we limited normoten-
sive controls to those older than 60 years of age to exclude erroneous control subjects with
late-onset hypertension. This strategy has been predicted to be a robust approach for gene-
association discovery [32]. Finally, we selected a northern Sardinian cohort for our studies as it
is a relatively isolated genetic population [33,34], thus reducing putative confounders from
genetic background heterogeneity and environmental factor variability. Our approach has
been successful in detecting strong associations not only for ATP1A1 but also for DEspR (dual
endothelin1/ vascular endothelial growth factor-signal peptide receptor) [35], NLRP6/AVR
(NLR family, pyrin domain containing 6/angiotensin-vasopressin receptor) and ADM
(adrenomedullin) [36] in the same Sardinian sample. It will be important to consider these
factors in testing not only the ATP1A1 12T-ins/del polymorphism but also other functional
gene variants for possible association with essential hypertension in other populations.
In summary, we have identified a 12T-insertion/deletion variant in the ATP1A1 promoter
region that is associated with decreased/increased susceptibility to essential hypertension in
males in a northern Sardinian population. The 12T-insertion variant exhibited decreased tran-
scriptional activity that could result in reduced expression of renal and endothelial a1 Na,K-
ATPase and eventually lower blood pressure among subjects harboring this variant. Although
replication in other human populations remains to be performed, our findings support the hy-
pothesis that the ATP1A1 gene is a susceptibility locus for essential hypertension in the setting




The Sardinian cohort study was performed in strict accordance with the principles expressed
in the Declaration of Helsinki. The protocol was approved by the local ethics committee of
Local Health Unit-University of Sassari Medical School. Written informed consent was ob-
tained and all clinical investigation was conducted according to the principles expressed in the
Declaration of Helsinki. The animal studies were performed in strict accordance with the rec-
ommendations in the Guide for the Care and Use of Laboratory Animals of the National Insti-
tutes of Health. The protocol was approved by the Institutional Animal Care and use
Committee on the Ethics of Animal Experiments of Boston University School of Medicine
(Permit Number: AN-14965). All surgery was performed under appropriate anesthesia, and
every effort was made to minimize suffering.
Study population
The study cohort has been previously described [14,16,35,36]. It consists of 712 subjects, 433
hypertensives and 279 normotensives, all enrolled at the Hypertension and Cardiovascular Pre-
vention Center of the University of Sassari Medical School, Sassari, Sardinia, Italy. Studies were
approved by the local ethics committee of Local Health Unit-University of Sassari Medical
School. All subjects were white, unrelated, born in different domains of North Sardinia previ-
ously ascertained to have a high degree of genetic homogeneity [33,34], ascertained to be Sar-
dinian for at least 6 generations, and resided in Sardinia. Hypertensive patients with BP> 160/
95 mmHg (n = 433), no secondary hypertension etiology and absence of major comorbid
12T-Insertion in ATP1A1 Promoter and Hypertension Susceptibility
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conditions were considered in the study. Older patients were included only if they were diag-
nosed as hypertensive well before 55 years of age. BP measurements were obtained with pa-
tients not taking any medications. Family history of hypertension was investigated, and a
complete pedigree was defined. To exclude erroneous control subjects with late-onset hyper-
tension, normotensive controls (n = 279) were limited to those older than 60 years of age who
had not been previously diagnosed or treated as hypertensive, had no family history of hyper-
tension and cardiovascular or cerebrovascular disease, and had BP values< 138/85 on at least
4 occasions.
Cloning and sequencing of ATP1A1 5’-regulatory regions
We cloned and sequenced a 4551 bp DNA fragment using the following primers: forward
primer: 50-AGA-TCA-TGA-GGC-TGA-GTG-AG-30 and reverse primer: 50-TTC-CAT-TTT-
GGC-GAT-GGT-G-30) encompassing chromosome-1 coordinates 116363538–116368089
(Homo sapiens chromosome 1 GRCh38 Primary Assembly) of the 5’-regulatory region of
ATP1A1 (Fig. 1) from six patients, three carrying haplotypes associated with hypertension and
three carrying haplotypes associated with normotension respectively. Each fragment was
subcloned into the PT-vector system (Clontech, Palo Alto, CA) and then sequenced in its
entirety in both directions.
Transcriptional activity of ATP1A1 promoter regions
Wemeasured transcriptional activity as described [35] using the SEAP Reporter System
(Clontech Lab,Inc.) which measures secreted alkaline phosphatase (SEAP) produced by the
transfected minigene construct. We cloned the ATP1A1 promoter regions onto pSEAP2 vector
generating two types of constructs: one carrying the 12T-insertion polymorphism (p12Tins,
Fig. 1C), and one containing the 12T-deletion polymorphism (p12Tdel, Fig. 1C). We measured
transcriptional activity in three cell lines, two of renal origin (HEK293, human embryonic
kidney cell line; Cos1, monkey kidney cell line) and one human mammary tumor cell line
(MDA-MB-468, ATCC) since ATP1A1 is expressed in all tissues and prominently in kidney
[4–6].
Transfections were performed as described [35]. Cells were co-transfected with 3.0 mg of 5’-
regulatory region-SEAP constructs plus 1.5 mg of pSV2-b-Galactosidase (for internal control)
using the DOTAP liposomal transfection reagent (Roche Molecular Biochemicals). After 72
hours, cell culture supernatants were collected and assayed for SEAP activity following manu-
facturer’s specifications. Cell protein extracts were utilized for determination of b-Galactosi-
dase activity (Promega) to normalize SEAP activity. Each construct was tested in six replicates
in the presence of standard tissue culture conditions containing 156 mMNa+ in the media,
which is expected to simulate high sodium levels that increase endothelial stiffness since levels
above 139 mM sodium increases endothelial stiffness [21].
Blood pressure measurements in ATP1A1+/− and wild type mice
We used B6;129S5-Atp1a1Gt(neo)311Lexmice (stock number: 011687-UCD) procured from the
Mutant Mouse Regional Resource Center (MMRRC) supported by NCRR-NIH. This ATP1A1
knockout line was developed by targeted retroviral insertion which occurred between exons
1 and 2 of the mouse ATP1A1 gene. Genetic data indicate that this retroviral insertion resulted in
lethality of the homozygous mutants. The line is maintained as a heterozygous line and available
with a mixed genetic background: 129/SvEvBrd × C57BL/6 hybrid. We inbred this line onto
C57BL/6 genetic background by speed-congenic backcross breeding as described [37]. Briefly, we
selected 20 males from a BC1 (backcross 1; B6;129S5-Atp1a1Gt(neo)311Lex × C57BL/6) generation
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that were genotyped with 142 SNPmarkers (custom performed by The Jackson Laboratory/JAX
Genome Scan service) informative for the 129/SvEvBrd × C57BL/6 cross and selected the best
male (carrying the least 129/SvEvBrd genetic background) as breeder for the production of a BC2
generation. Backcross breeding continued for additional four generations, BC5, which provided
all ATP1A1+/−mice for analyses with> 99.5% C57BL/6 genetic background. Animals utilized
for BP measurements were 3 months of age. Five wild-type and four ATP1A1+/− littermate male
mice were produced for the study from the same BC5 (+/+) × (+/−) intercross. Radiotelemetric
blood pressures were obtained as described [35]. Surgical implantation into the carotid artery
was done per manufacturer’s specifications using mouse radiotelemetric implants (PA-C10,
Dataquest A.R.T. 4.2 system from DATA SCIENCES INTERNATIONAL). Briefly, we obtained
blood pressure measurements taking the average over ten-seconds every 5 minutes for 24 hours
with no personnel entry during the time of recording. Systolic (SBP), diastolic (DBP) and mean
arterial pressures (MAP) were obtained along with heart rate and activity. Ideal conditions were
ascertained: from the time of surgery. In contrast to common practice in published literature, im-
planted mice were housed individually in cages placed over the telemetric receiver systems in a
room dedicated 24/7 for telemetric BP measurements with no other mouse cages in the room
other than the study mice. Importantly, since in vivo mouse studies were done in a dedicated
dual housing-measurement room, there are no confounders from having to move mice from
their housing room to a BP-telemetry room for measurement.
Western blot analysis
We analyzed 3 month-old ATP1A1+/− (n = 5 males) and wild type (n = 4 males) mice for
ATP1A1 protein levels by Western blot analysis as described [38], using equal amounts of pro-
tein (30mg) from mouse whole kidney extracts. A mouse monoclonal IgG anti-ATP1A1 specific
antibody (ab) (sc-21712, Santa Cruz Biotechnology; 1:500 dilution, primary antibody incuba-
tion for 16 hours at 4°C) was used to detect ATP1A1-specific polypeptide [38]. An anti-bActin
specific antibody (sc-47778, Santa Cruz Biotechnology) was used as control for densitometry
analysis.
Genotyping
Genotyping was performed with a PCR-based ATP1A1-specific fragment (174 bp). The PCR
product (forward primer: 50-ACT-GTG-TCC-ATG-ACC-AGA-C-30; reverse primer: 50-TTC-
AAG-ACC-AGC-CTG-AGT-G-30) contained the 12T-ins/del polymorphism within the 5’reg-
ulatory region. Alleles (12T-ins and 12T-del) were identified and distinguished from each
other by 6% sequencing polyacrylamide gel electrophoresis (Fig. 1A) as described [16]. The
genotyping completeness rate was 87%.
Statistical analysis
Single point association analysis comparing case and control subjects was done with the SNP &
Variation Suite genetic analysis software (version 6.4.3, released on 03-25-2009, Golden Helix
Inc., Bozeman, MT, USA). A basic allelic test (D vs d) was implemented using Fisher’s exact
test as statistical method obtaining odds ratios with corresponding confidence limits. The miss-
ing genotypes were not included (imputed) in the association analysis. Analysis of blood pres-
sure as a quantitative trait was performed using two-sided student t-test (SigmaPlot 11.0)
comparing blood pressure levels in homozygous 12T-del/del carriers versus subjects carrying
[12T-ins/del + 12T-ins/ins] genotypes.
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S1 Fig. Location of putative ATP1A1 RNA initiation site. (A) Human chromosome 1 map
(116363000–116405000) with ATP1A1 location notated (Homo sapiens Annotation Release
106), along with Hs RNA map and RefSeq RNA map spanning ATP1A1 gene. Potential RNA
initiation site is noted at 116366000 with predicted exon 1 (5’-Untranslated region) supported
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